ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Taipei City, TWN:

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 31 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Taipei City, Taiwan and 228 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 516 other locations

Status recently updated

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Enrolling
Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Taipei, Taiwan and 108 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 121 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Taipei, Taiwan and 505 other locations

, and anti-tumor activity of each regimen at the MTD/RD....

Active, not recruiting
Triple Negative Breast Cancer
Microsatellite Stable Colorectal Cancer
Drug: DKY709
Drug: PDR001

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Beitou, Taiwan and 192 other locations

with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: nab-paclitaxel
Drug: placebo

Phase 3

Novartis
Novartis

Taipei, Taiwan and 76 other locations

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

Phase 3

OBI Pharma

Taipei, Taiwan and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems